期刊
FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.1027664
关键词
ctDNA; liquid biopsy; NSCLC; therapy monitoring; minimal residual disease (MRD)
类别
资金
- National Natural Science Foundation of China
- Jiangsu National Natural Science Foundation
- [81902327]
- [82172708]
- [BK20191064]
ctDNA is a valuable detection tool for evaluating tumor burden, specific cancer mutations, and minimal residual disease. Recent clinical trials have shown the rationality and feasibility of using ctDNA to identify mutations and guide treatments in non-small cell lung cancer (NSCLC).
Circulating tumor DNA (ctDNA) has contributed immensely to the management of hematologic malignancy and is now considered a valuable detection tool for solid tumors. ctDNA can reflect the real-time tumor burden and be utilized for analyzing specific cancer mutations via liquid biopsy which is a non-invasive procedure that can be used with a relatively high frequency. Thus, many clinicians use ctDNA to assess minimal residual disease (MRD) and it serves as a prognostic and predictive biomarker for cancer therapy, especially for non-small cell lung cancer (NSCLC). Advanced methods have been developed to detect ctDNA, and recent clinical trials have shown the rationality and feasibility of ctDNA for identifying mutations and guiding treatments in NSCLC. Here, we have reviewed recently developed ctDNA detection methods and the importance of sequence analyses of ctDNA in NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据